Clinical Data Announces Exercise of Underwriters' Over-Allotment Option
Jul 24, 2007

NEWTON, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Clinical Data, Inc. (NASDAQ: CLDA) today announced that the underwriters of its public offering that closed on July 23, 2007 have exercised an over-allotment option to purchase an additional 450,000 shares of common stock from Clinical Data. After giving effect to the exercise of the over-allotment option, Clinical Data will issue 3,450,000 shares of common stock in the offering and expects to receive aggregate net proceeds of approximately $71.5 million after underwriting discounts and commissions. The company currently expects to use the net proceeds of this offering to fund clinical trial activities, preclinical research and development activities and for other general corporate purposes, including the acquisition of complementary businesses and technologies, capital expenditures and working capital. All of the shares are being offered by Clinical Data pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.

Clinical Data's largest stockholder and Chairman of its Board of Directors, Randal J. Kirk, who purchased, through one or more of his affiliates an aggregate of 2,250,000 shares of the common stock in the offering, will own, directly or through his affiliates, approximately 46% of the issued and outstanding common stock of Clinical Data after giving effect to the exercise of the underwriters' over-allotment option.

Bear, Stearns & Co. Inc. is the sole book-running manager of the offering with Lazard Capital Markets LLC acting as co-manager. The purchase of the shares being sold pursuant to the exercise of the underwriters' over-allotment option is expected to close on or about July 26, 2007, subject to customary conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the prospectus supplement and related prospectus relating to this offering may be obtained from Bear, Stearns & Co. Inc., 383 Madison Avenue, New York, NY 10179, Attn: Prospectus Department, or by phone at (866) 803-9204.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide.

Internet Website: www.clda.com

SOURCE: Clinical Data, Inc.

Clinical Data, Inc.
	Investors:
	Stephanie Carrington/Sara Ephraim, 1-646-536-7017/7002
	or
	Media:
	Jason Rando/Janine McCargo, 1-646-536-7025/7033

Copyright Business Wire 2007

News Provided by COMTEX